Background: Inflammatory bowel disease (IBD) is a chronically relapsing disease with a
continuous need for proactive monitoring to decide appropriate treatments and follow-up …

Dipeptidyl-peptidase IV (DPP4), originally identified as an aminopeptidase in 1960s, is an
ubiquitously expressed protease presented as either a membrane-bound or soluble form …

Despite considerable epidemiological evidence indicating comorbidity between metabolic
disorders, such as obesity, type 2 diabetes, and non-alcoholic fatty liver disease, and …

Introduction Ulcerative colitis (UC) is a chronic illness requiring lifelong management that
could be enhanced by personalizing care using biomarkers. Areas covered The main …

Diagnosing inflammatory bowel disease (IBD) can often be challenging, and differentiating
between Crohn's disease and ulcerative colitis can be particularly difficult. Diagnostic …

Along with social development and lifestyle changes, the number of overweight and obese
patients worldwide is rising annually. Obesity is a chronic metabolic disease with complex …

Abstract Dipeptidyl peptidase-4 inhibitors (DPP-4i) have an important place in the
management of type 2 diabetes. The DPP-4 enzyme is ubiquitously distributed throughout …

Prolyl-specific peptidases or proteases, including Dipeptidyl Peptidase 2, 4, 6, 8, 9, 10,
Fibroblast Activation Protein, prolyl endopeptidase, and prolyl carboxypeptidase, belong to …

Simple Summary Prognostic markers have become a promising tool for predicting response
to a certain treatment and qualifying patients for a certain therapy; however, it is important to …

Abstract DPP4 (Dipeptidyl-peptidase 4) a versatile protease, emerges as a prominent player
in soluble and membrane-bound forms. Its heightened expression has been intimately …